MedTrace Logo

Plasmalyte-148 Solution and Blood Coagulation

NCT03168087 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2020-02-13

No results posted yet for this study

Summary

Fluids administered intravenously may alter whole blood coagulation. However, little is known about the dose-response relationships of hemodilution in plasmalyte-148 solution. Investigators have therefore performed the present study to measure the effect of a plasmalyte-148 solution on the coagulation pathway according to the hemodilution level using a rotational thromboelastometry (ROTEM®) tests.

Conditions

  • Blood Coagulation Disorder

Interventions

OTHER

Plasmalyte-148

Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Hyun-Jung Shin, PhD · Seoul National University Bundang Hospital

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-15
Primary Completion
2018-08-23
Completion
2018-08-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03168087 on ClinicalTrials.gov